Engineering immunogenic cell death with nanosized drug delivery systems improving cancer immunotherapy. (December 2020)

• Record Type: Journal Article
• Authors: Yan, Wenlu; Lang, Tianqun; Qi, Xianrong; Li, Yaping
• Is Part Of: Current opinion in biotechnology. Volume 66(2020)
• Page Start: 36
• Page End: 43
• Publication Date: 2020-12
• Subjects: Biotechnology -- Periodicals; 660.6
• DOI: 10.1016/j.copbio.2020.06.007
• Languages: English
• ISSNs: 0958-1669

Abstract

Highlights: The immunogenic cell death (ICD) of cancer cells promotes immune response. Nanosized drug delivery systems can induce ICD. Anti-cancer nanomedicines reduce systemic side effects and enhance tumor targeting capacity. Different strategies for inducing ICD improve the efficacy of cancer immunotherapy. Abstract : Many anti-cancer therapies can induce or enhance the immunogenic cell death (ICD), a process that releases damage-associated molecular patterns (DAMPs) to prime antigen processing and presentation necessary for successful cancer immunotherapy. However, the clinical potential of these therapies, especially the chemotherapy, is limited by serious systemic side effects, because of their non-specific accumulation out of the tumors. Nanosized drug delivery systems (NDDSs) can improve the specificity of anti-cancer therapies, which enhance ICD in the tumor while alleviating toxicities. In this review, we summarize recent progress of ICD-inducing NDDSs with a focus on their enhanced safety and efficacy for cancer immunotherapy.